company background image
PKI

PerkinElmerNYSE:PKI Stock Report

Last Price

US$174.88

Market Cap

US$22.1b

7D

-2.0%

1Y

15.1%

Updated

23 Jan, 2022

Data

Company Financials +
PKI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health3/6
Dividends0/6

PKI Stock Overview

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide.

PerkinElmer Competitors

Thermo Fisher Scientific

NYSE:TMO

US$228.7b

Agilent Technologies

NYSE:A

US$41.5b

Mettler-Toledo International

NYSE:MTD

US$33.5b

West Pharmaceutical Services

NYSE:WST

US$27.2b

Price History & Performance

Summary of all time highs, changes and price drops for PerkinElmer
Historical stock prices
Current Share PriceUS$174.88
52 Week HighUS$203.16
52 Week LowUS$119.95
Beta1.08
1 Month Change-9.75%
3 Month Change-1.30%
1 Year Change15.12%
3 Year Change102.20%
5 Year Change234.25%
Change since IPO1,927.59%

Recent News & Updates

Dec 27
With EPS Growth And More, PerkinElmer (NYSE:PKI) Is Interesting

With EPS Growth And More, PerkinElmer (NYSE:PKI) Is Interesting

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

PKIUS Life SciencesUS Market
7D-2.0%-4.7%-6.1%
1Y15.1%1.8%4.2%

Return vs Industry: PKI exceeded the US Life Sciences industry which returned 1.8% over the past year.

Return vs Market: PKI exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is PKI's price volatile compared to industry and market?
PKI volatility
PKI Average Weekly Movement4.2%
Life Sciences Industry Average Movement9.1%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: PKI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PKI's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
193714,000Prahlad Singhhttps://www.perkinelmer.com

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

PerkinElmer Fundamentals Summary

How do PerkinElmer's earnings and revenue compare to its market cap?
PKI fundamental statistics
Market CapUS$22.07b
Earnings (TTM)US$1.13b
Revenue (TTM)US$5.06b

19.5x

P/E Ratio

4.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PKI income statement (TTM)
RevenueUS$5.06b
Cost of RevenueUS$2.10b
Gross ProfitUS$2.95b
ExpensesUS$1.82b
EarningsUS$1.13b

Last Reported Earnings

Oct 03, 2021

Next Earnings Date

Feb 01, 2022

Earnings per share (EPS)8.98
Gross Margin58.39%
Net Profit Margin22.41%
Debt/Equity Ratio73.3%

How did PKI perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

3%

Payout Ratio

Valuation

Is PerkinElmer undervalued compared to its fair value and its price relative to the market?

10.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PKI ($174.88) is trading below our estimate of fair value ($196.32)

Significantly Below Fair Value: PKI is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PKI is good value based on its PE Ratio (19.5x) compared to the US Life Sciences industry average (39.3x).

PE vs Market: PKI is poor value based on its PE Ratio (19.5x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: PKI's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PKI's PB Ratio (3.2x) is in line with the US Life Sciences industry average.


Future Growth

How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

-8.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PKI's earnings are forecast to decline over the next 3 years (-8.2% per year).

Earnings vs Market: PKI's earnings are forecast to decline over the next 3 years (-8.2% per year).

High Growth Earnings: PKI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PKI's revenue is expected to decline over the next 3 years (-0.4% per year).

High Growth Revenue: PKI's revenue is forecast to decline over the next 3 years (-0.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PKI's Return on Equity is forecast to be low in 3 years time (16.4%).


Past Performance

How has PerkinElmer performed over the past 5 years?

42.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PKI has high quality earnings.

Growing Profit Margin: PKI's current net profit margins (22.4%) are higher than last year (12.7%).


Past Earnings Growth Analysis

Earnings Trend: PKI's earnings have grown significantly by 42.6% per year over the past 5 years.

Accelerating Growth: PKI's earnings growth over the past year (175.9%) exceeds its 5-year average (42.6% per year).

Earnings vs Industry: PKI earnings growth over the past year (175.9%) exceeded the Life Sciences industry 72.2%.


Return on Equity

High ROE: PKI's Return on Equity (16.3%) is considered low.


Financial Health

How is PerkinElmer's financial position?


Financial Position Analysis

Short Term Liabilities: PKI's short term assets ($2.3B) exceed its short term liabilities ($1.1B).

Long Term Liabilities: PKI's short term assets ($2.3B) do not cover its long term liabilities ($6.8B).


Debt to Equity History and Analysis

Debt Level: PKI's net debt to equity ratio (66.3%) is considered high.

Reducing Debt: PKI's debt to equity ratio has increased from 51.2% to 73.3% over the past 5 years.

Debt Coverage: PKI's debt is well covered by operating cash flow (30.5%).

Interest Coverage: PKI's interest payments on its debt are well covered by EBIT (19.5x coverage).


Balance Sheet


Dividend

What is PerkinElmer current dividend yield, its reliability and sustainability?

0.16%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PKI's dividend (0.16%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.37%).

High Dividend: PKI's dividend (0.16%) is low compared to the top 25% of dividend payers in the US market (3.6%).


Stability and Growth of Payments

Stable Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: PKI is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PKI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Prahlad Singh (56 yo)

3yrs

Tenure

US$9,017,969

Compensation

Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of PerkinElmer, Inc. since December 30, 2019. Dr. Singh serves as the Chairman of the Supervisory Board at EUROIMMUN Medizinische Labordiagnos...


CEO Compensation Analysis

Compensation vs Market: Prahlad's total compensation ($USD9.02M) is about average for companies of similar size in the US market ($USD11.47M).

Compensation vs Earnings: Prahlad's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: PKI's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: PKI's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.


Top Shareholders

Company Information

PerkinElmer, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: PerkinElmer, Inc.
  • Ticker: PKI
  • Exchange: NYSE
  • Founded: 1937
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$22.070b
  • Shares outstanding: 126.20m
  • Website: https://www.perkinelmer.com

Number of Employees


Location

  • PerkinElmer, Inc.
  • 940 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:20
End of Day Share Price2022/01/21 00:00
Earnings2021/10/03
Annual Earnings2021/01/03


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.